Clinical Scorecard: Fulminant-like Diabetes and Hyperosmolar Hyperglycemic State Associated with Inavolisib: A Case Study

At a Glance

Key Highlights

• Rapid-onset severe hyperglycemia can occur within 72 hours of Inavolisib initiation.
• Normal baseline glycemic indices do not exclude the risk of severe hyperglycemia.
• Prompt insulin-based management is crucial for resolution of hyperglycemia.
• Close glucose monitoring is essential in patients receiving Inavolisib.
• Discontinuation of Inavolisib is necessary when hyperglycemia is clinically significant.

Guideline-Based Recommendations

Diagnosis

• Monitor blood glucose levels regularly in patients starting Inavolisib.
• Assess for signs of Hyperosmolar Hyperglycemic State (HHS) in symptomatic patients.

Management

• Discontinue Inavolisib if severe hyperglycemia or HHS develops.
• Initiate intensive insulin therapy for rapid control of blood glucose.

Monitoring & Follow-up

• Conduct regular metabolic assessments including blood glucose and HbA1c.
• Monitor electrolytes and osmolarity in patients with hyperglycemia.

Risks

• Inavolisib is associated with a significant risk of hyperglycemia and HHS.
• Patients without prior diabetes may develop fulminant-like diabetes.

Patient & Prescribing Data

Patients with metastatic breast cancer, particularly those with PIK3CA mutations.

Inavolisib should be used with caution due to its potential to induce severe hyperglycemia.

Clinical Best Practices

• Educate patients about the risk of hyperglycemia when starting Inavolisib.
• Implement a proactive glucose monitoring strategy for early detection of hyperglycemia.
• Ensure interdisciplinary communication between oncology and endocrinology teams.

Related Resources & Content

• Inavolisib Package Insert
• Clinical Guidelines on Hyperglycemia Management